A Review of Cannabis and Interactions With Anticoagulant and Antiplatelet Agents

  title={A Review of Cannabis and Interactions With Anticoagulant and Antiplatelet Agents},
  author={Jessica Greger and V. Bates and Laszlo L Mechtler and F. Gengo},
  journal={The Journal of Clinical Pharmacology},
  • Jessica Greger, V. Bates, +1 author F. Gengo
  • Published 2019
  • Medicine
  • The Journal of Clinical Pharmacology
  • Legalization of medical cannabis has occurred in 33 states and the District of Columbia, and recreational use has increased exponentially since 2013. As a result, it is important to understand how cannabis interacts with other drugs and has potential risks for patients on concomitant medications. Components of medical cannabis can inhibit or compete for several cytochrome P450 (CYP) hepatic isoenzymes, UDP‐glucuronosyltransferases, and P‐glycoprotein. These enzymes and transporters are involved… CONTINUE READING
    5 Citations


    Interaction between warfarin and cannabis
    • 25
    Evaluating the Effect of Six Proton Pump Inhibitors on the Antiplatelet Effects of Clopidogrel.
    • 4
    New Direct Oral Anticoagulants (DOAC) and Their Use Today
    • 14
    • PDF
    Novel antiplatelet agents in acute coronary syndrome
    • 224
    Pharmacokinetic and Pharmacodynamic Responses to Clopidogrel: Evidences and Perspectives
    • 16
    • PDF
    Pharmacokinetics and Pharmacodynamics of Cannabinoids
    • 822
    • PDF